Ovarian cancer drug will cost HAs millions
Health authorities will have to find millions of pounds to fund cancer drugs after the National Institute for Clinical Excellence backed the use of paclitaxel to treat patients with ovarian cancer.
You need to be an HSJ subscriber to read more
Subscribe to read the full article
With an HSJ subscription you’ll get access to:
- Expert Briefing newsletters, covering nine topics and regions
- Weekly Catch Up – a summary of the week’s most important stories
- Unlimited access to hsj.co.uk
- The HSJ app
Enquire about multi-user access